Key facts
- Only 24% of US pharmaceutical executives believe AI will be crucial for drug-making in the next five years.
- China is actively adopting AI in its pharmaceutical industry.
- The survey surveyed 100 US pharmaceutical executives.
Despite the rapid advancements and increasing integration of artificial intelligence across various industries, a significant portion of US pharmaceutical executives remain hesitant about its immediate impact on drug development. A recent survey revealed that only 24% of these executives believe AI will play a crucial role in their companies' drug-making processes within the next five years. This contrasts sharply with China's proactive embrace of AI in its pharmaceutical sector, indicating a divergence in strategic outlook and adoption rates between the two major global economies. The survey polled 100 executives from the US pharmaceutical industry, highlighting a cautious sentiment regarding the transformative potential of AI in drug discovery and manufacturing.